Cyclacel Pharmaceuticals (CYCC)
(Delayed Data from NSDQ)
$1.02 USD
-0.01 (-0.97%)
Updated Sep 17, 2024 03:12 PM ET
After-Market: $1.01 -0.01 (-0.98%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth B Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CYCC 1.02 -0.01(-0.97%)
Will CYCC be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CYCC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CYCC
Cyclacel Pharmaceuticals (CYCC) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q2 Loss, Misses Revenue Estimates
CYCC: What are Zacks experts saying now?
Zacks Private Portfolio Services
VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Lags Revenue Estimates
Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Lags Revenue Estimates
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates
Other News for CYCC
Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference
Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter
Cyclacel files an appeal to Nasdaq delisting letter
Cyclacel Pharmaceuticals confirms filing of appeal to Nasdaq delisting letter
Why Zhibao Technology Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket